Fostemsavir (GSK3684934) (ViiV Healthcare), previously known as BMS-663068, is an oral prodrug of GSK2616713 (formerly BMS-626529). It is an attachment inhibitor which binds to the gp120 protein of HIV to prevent viral attachment to the host CD4+ T cells, which is necessary for entry into host cells.
Leronlimab (CytoDyn) is a humanized monoclonal antibody directed against C-C chemokine receptor 5 (CCR5), which is a co-receptor required for the attachment and entry of CCR5-tropic HIV-1 viruses into host cells.
Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson & Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.
Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.
The Reyataz franchise comprises the standalone azapeptide protease inhibitor (PI) Reyataz (atazanavir; Bristol-Myers Squibb) and the fixed-dose combination of Reyataz and Tybost.
Isentress (raltegravir; Merck & Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.
Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Japan Tobacco) is a single-tablet regimen for the treatment of HIV-1 infection. It is a co-formulation of marketed fixed-dose combination (FDC) Truvada, Vitekta, and Tybost.
The Prezista franchise comprises the standalone protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson) and the fixed-dose combination of Prezista and Tybost (cobicistat; Gilead), which is branded as Prezcobix in the US and Rezolsta in the EU.
Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ViiV Healthcare) and Epzicom ([abacavir + lamivudine]; ViiV Healthcare), which is known as Kivexa outside the US. Tivicay is an integrase inhibitor that blocks the insertion of the viral genome into the host genome, and Epzicom is a fixed-dose combination nucleoside reverse transcriptase inhibitor that prevents viral RNA replication.
Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.
Fetzima (levomilnacipran; Allergan) is a serotonin-norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in the US.
Travivo (gepirone ER; GlaxoSmithKline/Mission Pharmacal) is a pyridinyl piperazine 5-HT1A receptor agonist, and is distinct from available therapies as it is not a reuptake inhibitor and has no material norepinephrine or dopamine activity. Unlike tricyclic antidepressants or selective serotonin reuptake inhibitors that act on most or all of the 5-HT subtypes in the brain and may have several adverse effects, trials for Travivo have shown benign adverse effects without significant dopaminergic effects.
SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) is a novel, next-generation positive allosteric modulator that selectively binds synaptic and extrasynaptic gamma-aminobutyric acid-A (GABA-A) receptors and shares similar pharmacology properties to brexanolone.
Zulresso is SAGE Therapeutics’ proprietary intravenous formulation of brexanolone, which is an allosteric modulator of both synaptic and extra-synaptic GABA-A receptors.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!